Who owns BioNTech SE?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of BNTX from SEC Form 13F filings across 301 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 301 institutions disclosed 47.4M shares of BioNTech SE worth $4.65B — about 19.6% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
301
13F holders
$4.65B
value, 2026 filers
19.6%
of shares outstanding (47.4M sh)
60
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of BNTX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 9.8M | $963.1M | 0.0% | 4.1% | +29.4% |
| 2 | PRIMECAP MANAGEMENT CO/CA/ | 3.8M | $368.9M | 0.2% | 1.6% | -0.5% |
| 3 | Dodge & Cox | 3.7M | $362.5M | 0.2% | 1.5% | +0.3% |
| 4 | BlackRock, Inc. | 1.8M | $180.4M | 0.0% | 0.8% | -1.1% |
| 5 | BNP PARIBAS FINANCIAL MARKETS | 1.3M | $126.0M | 0.0% | 0.5% | -2.8% |
| 6 | T. Rowe Price Investment Management, Inc. | 1.2M | $121.9M | 0.1% | 0.5% | -39.9% |
| 7 | Temasek Holdings (Private) Ltd | 1.2M | $121.5M | 0.3% | 0.5% | -17.9% |
| 8 | FIRST TRUST ADVISORS LP | 996,312 | $97.9M | 0.1% | 0.4% | +25.9% |
| 9 | D. E. Shaw & Co., Inc. | 974,861 | $95.8M | 0.0% | 0.4% | +133.5% |
| 10 | GOLDMAN SACHS GROUP INC | 863,731 | $84.9M | 0.0% | 0.4% | +46.4% |
| 11 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 800,878 | $78.7M | 0.0% | 0.3% | +7.6% |
| 12 | Assenagon Asset Management S.A. | 760,675 | $74.8M | 0.1% | 0.3% | +79.7% |
| 13 | Davern Capital Partners, LP | 682,148 | $67.1M | 13.0% | 0.3% | -9.6% |
| 14 | TWO SIGMA INVESTMENTS, LP | 671,698 | $66.0M | 0.0% | 0.3% | +129.6% |
| 15 | GSK plc | 668,526 | $65.7M | 13.2% | 0.3% | -24.9% |
| 16 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 666,194 | $65.5M | 0.0% | 0.3% | -1.7% |
| 17 | Logos Global Management LP | 650,000 | $63.9M | 3.4% | 0.3% | -36.0% |
| 18 | MARSHALL WACE, LLP | 639,040 | $62.8M | 0.1% | 0.3% | +67.2% |
| 19 | MILLENNIUM MANAGEMENT LLCNEW | 637,768 | $62.7M | 0.0% | 0.3% | new |
| 20 | Long Focus Capital Management, LLC | 632,000 | $62.1M | 1.7% | 0.3% | +1.3% |
| 21 | FRANKLIN TEMPLETON INC | 630,047 | $57.1M | 0.0% | 0.3% | +16.8% |
| 22 | CITADEL ADVISORS LLC | 572,754 | $56.3M | 0.0% | 0.2% | +57.1% |
| 23 | VICTORY CAPITAL MANAGEMENT INC | 572,098 | $56.2M | 0.0% | 0.2% | +6.0% |
| 24 | SAMLYN CAPITAL, LLCNEW | 561,697 | $55.2M | 0.9% | 0.2% | new |
| 25 | Candriam S.C.A. | 520,972 | $51.4M | 0.2% | 0.2% | +4.7% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.